Therapeutic Drug Monitoring in Oncology

International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

Jan H. Beumer, Edward Chu, Carmen Allegra, Yusuke Tanigawara, Gerard Milano, Robert B Diasio, Tae Won Kim, Ron H. Mathijssen, Li Zhang, Dirk Arnold, Katsuki Muneoka, Narikazu Boku, Markus Joerger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

Original languageEnglish (US)
JournalClinical Pharmacology and Therapeutics
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Drug Monitoring
Fluorouracil
Toxicology
Body Surface Area
Head and Neck Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Therapeutic Drug Monitoring in Oncology : International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. / Beumer, Jan H.; Chu, Edward; Allegra, Carmen; Tanigawara, Yusuke; Milano, Gerard; Diasio, Robert B; Kim, Tae Won; Mathijssen, Ron H.; Zhang, Li; Arnold, Dirk; Muneoka, Katsuki; Boku, Narikazu; Joerger, Markus.

In: Clinical Pharmacology and Therapeutics, 01.01.2018.

Research output: Contribution to journalArticle

Beumer, Jan H. ; Chu, Edward ; Allegra, Carmen ; Tanigawara, Yusuke ; Milano, Gerard ; Diasio, Robert B ; Kim, Tae Won ; Mathijssen, Ron H. ; Zhang, Li ; Arnold, Dirk ; Muneoka, Katsuki ; Boku, Narikazu ; Joerger, Markus. / Therapeutic Drug Monitoring in Oncology : International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. In: Clinical Pharmacology and Therapeutics. 2018.
@article{1ba77b98fa3e4053b4b999c4e487c08b,
title = "Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy",
abstract = "5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.",
author = "Beumer, {Jan H.} and Edward Chu and Carmen Allegra and Yusuke Tanigawara and Gerard Milano and Diasio, {Robert B} and Kim, {Tae Won} and Mathijssen, {Ron H.} and Li Zhang and Dirk Arnold and Katsuki Muneoka and Narikazu Boku and Markus Joerger",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cpt.1124",
language = "English (US)",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Therapeutic Drug Monitoring in Oncology

T2 - International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy

AU - Beumer, Jan H.

AU - Chu, Edward

AU - Allegra, Carmen

AU - Tanigawara, Yusuke

AU - Milano, Gerard

AU - Diasio, Robert B

AU - Kim, Tae Won

AU - Mathijssen, Ron H.

AU - Zhang, Li

AU - Arnold, Dirk

AU - Muneoka, Katsuki

AU - Boku, Narikazu

AU - Joerger, Markus

PY - 2018/1/1

Y1 - 2018/1/1

N2 - 5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

AB - 5-Fluorouracil (5-FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5-FU therapy in patients with colorectal or head-and-neck cancer receiving common 5-FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.

UR - http://www.scopus.com/inward/record.url?scp=85053435195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053435195&partnerID=8YFLogxK

U2 - 10.1002/cpt.1124

DO - 10.1002/cpt.1124

M3 - Article

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

ER -